A sting in the tail: the N-terminal domain of the androgen receptor as a drug target

Abstract excerpt

The role of androgen receptor (AR) in the initiation and progression of prostate cancer (PCa) is well established. Competitive inhibition of the AR ligand-binding domain (LBD) has been the staple of antiandrogen therapies employed to combat the disease in recent years. However, their efficacy has often been limited by the emergence of resistance, mediated through point mutations, and receptor truncations. As a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Estrogen and related hormone effects
• Share to Hormonal and reproductive studies
• Share to Prostate Cancer Treatment and Research